24例成人LGMDR12患者为期2年前瞻性自然史研究:定量MRI与临床结局指标
这项前瞻性自然史研究纳入24例基因确诊的成人LGMDR12患者和24例年龄、性别匹配的健康对照,在基线、1年和2年评估6分钟步行距离、10米步行试验、MRC总分、Biodex等长测力、血清肌酸激酶和大腿6点Dixon MRI。结果显示,基线大腿肌肉脂肪替代处于中间阶段(PDFF 20%-70%)的患者1年后14块评估肌肉中8块PDFF升高,2年内6块个体肌肉PDFF标准化反应均数显示高反应性;早期(<20%)或终末期(>70%)患者PDFF在2年内无显著升高。Biodex等长测力显示1年后所有患者左右腘绳肌和右股四头肌肌力显著下降,而6MWD、10MWT和MRC总分即使2年后也未检测到显著下降。
要点
- 基线PDFF 20%-70%的LGMDR12患者1年后14块大腿肌肉中8块PDFF升高
- 早期(<20%)或终末期(>70%)脂肪替代患者2年内PDFF无显著升高
- Biodex等长测力可检测1年内肌力下降,6MWD、10MWT和MRC总分2年内未检测到显著下降
核心结论
- 大腿肌肉PDFF成像是追踪特定LGMDR12患者进行性肌肉脂肪替代的敏感结局指标,随访1年后即可检测到变化,并与临床结局指标相关。
- Biodex等长测力能可靠捕捉LGMDR12患者1年内肌力丧失,应作为未来临床试验的结局指标之一。
研究设计与样本
- 前瞻性自然史研究,纳入24例基因确诊的成人LGMDR12患者和24例年龄、性别匹配的健康对照。
- 在基线、1年和2年评估6分钟步行距离、10米步行试验、MRC总分、Biodex等长测力、血清肌酸激酶和大腿6点Dixon MRI。
主要发现
- 基线大腿肌肉脂肪替代处于中间阶段(PDFF 20%-70%)的患者,1年后14块评估肌肉中8块PDFF升高。
- 该组患者2年内6块个体肌肉PDFF的标准化反应均数显示高反应性。
- 早期(<20%)或终末期(>70%)肌肉脂肪替代患者,2年随访PDFF无显著升高。
- Biodex等长测力显示1年随访后所有患者左右腘绳肌肌力分别下降6.2 Nm(p<0.002)和4.6 Nm(p<0.009),右股四头肌下降9 Nm(p=0.044)。
- 6MWD、10MWT和MRC总分即使2年后也未检测到肌肉功能/力量显著下降;基线时总大腿PDFF与临床结局指标呈中等强度相关。
临床怎么用
- 作者认为大腿肌肉PDFF成像可作为追踪特定LGMDR12患者肌肉脂肪替代的敏感结局指标。
- 作者认为Biodex等长测力应作为未来临床试验的结局指标之一。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Limb-girdle muscular dystrophy autosomal recessive type 12 (LGMDR12) is a rare hereditary muscular dystrophy for which outcome measures are currently lacking. We evaluated quantitative MRI and clinical outcome measures to track disease progression to determine which tests could be useful in future clinical trials to evaluate potential therapies. METHODS: We prospectively measured the following outcome measures in all participants at baseline and after 1 and 2 years: 6-minute walk distance (6MWD), 10-meter walk test (10MWT), the Medical Research Council (MRC) sum scores, Biodex isometric dynamometry, serum creatine kinase, and 6-point Dixon MRI of the thighs. RESULTS: We included 24 genetically confirmed, adult patients with LGMDR12 and 24 age-matched and sex-matched healthy controls. Patients with intermediate-stage thigh muscle fat replacement at baseline (proton density fat fraction [PDFF] 20%-70%) already showed an increase in PDFF in 8 of the 14 evaluated thigh muscles after 1 year. The standardized response mean demonstrated a high responsiveness to change in PDFF for 6 individual muscles over 2 years in this group. However, in patients with early-stage (<20%) or end-stage (>70%) muscle fat replacement, PDFF did not increase significantly over 2 years of follow-up. Biodex isometric dynamometry showed a significant decrease in muscle strength in all patients in the right and left hamstrings (-6.2 Nm, p < 0.002 and -4.6 Nm, p < 0.009, respectively) and right quadriceps muscles (-9 Nm, p = 0.044) after 1 year of follow-up, whereas the 6MWD, 10MWT, and MRC sum scores were not able to detect a significant decrease in muscle function/strength even after 2 years. There was a moderately strong correlation between total thigh PDFF and clinical outcome measures at baseline. DISCUSSION: Thigh muscle PDFF imaging is a sensitive outcome measure to track progressive muscle fat replacement in selected patients with LGMDR12 even after 1 year of follow-up and correlates with clinical outcome measures. Biodex isometric dynamometry can reliably capture the loss of muscle strength over the course of 1 year in patients with LGMDR12 and should be included as an outcome measure in future clinical trials as well.
引用
- De Wel B, Huysmans L, Peeters R, et al. Prospective Natural History Study in 24 Adult Patients With LGMDR12 Over 2 Years of Follow-up: Quantitative MRI and Clinical Outcome Measures. Neurology. 2022. PMID: 35577579. doi:10.1212/WNL.0000000000200708
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。